ShareSoc Investor Presentation

Genedrive PLC

13 August 2026

 

13 August 2026

genedrive plc

("genedrive" or the "Company")

ShareSoc investor presentation  

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it will be presenting a live ShareSoc webinar on Thursday 3 September 2026 at 11:00am (BST).

Dr Gino Miele, Chief Executive Officer, and Russ Shaw, Chief Financial Officer, will provide an update on the Company's commercial and operational progress followed by a Q&A session. No new financial information will be disclosed during the event.

The presentation is open to all existing and potential shareholders. Further details, along with a registration form, are available here:

https://www.sharesoc.org/events/sharesoc-webinar-with-genedrive-gdr/

For further information, please contact:

genedrive plc	[phone]
Gino Miele: CEO / Russ Shaw: CFO	https://investors.genedrive.com/s/e0025c
Peel Hunt LLP (Nominated Adviser and Broker)	[phone]
James Steel
5654 & Company (Media & Investor Relations)	[e-mail]
Matthew Neal	[phone]
Melissa Gardiner	[phone]

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 

About genedrive plc (http://www.genedrive.com).

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

 

END